Baxter International (BAX) : The consensus on Baxter International (BAX) based on 11 analyst recommendation on the company stock is 2.94, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 9 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Baxter International (BAX) : The most positive equity analysts on Baxter International (BAX) expects the shares to touch $60, whereas, the least positive believes that the stock will trade at $46 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $48.83 with an expected fluctuation of $5.49 from the mean.
Baxter International (NYSE:BAX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $45.23 and $44.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $46.11. The buying momentum continued till the end and the stock did not give up its gains. It closed at $45.99, notching a gain of 1.50% for the day. The total traded volume was 4,877,019 . The stock had closed at $45.31 on the previous day.
Also, Evercore ISI Group initiates coverage on Baxter International (NYSE:BAX). The current rating of the shares is Buy, according to the research report released by the firm. The rating by the firm was issued on May 4, 2016. The company shares have rallied 24.14% from its 1 Year high price. On May 12, 2016, the shares registered one year high at $46.95 and the one year low was seen on Oct 6, 2015. The 50-Day Moving Average price is $44.14 and the 200 Day Moving Average price is recorded at $40.93.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.